Table 1.

Clinical data of 11 patients who developed CIP following ICIs treatment cessation

Author	Patient’s disease	Age	Sex	Clinical Manifestations	Imaging Findings	Type of ICIs	Time interval from drug withdrawal to CIP onset	CIP grade	Treatments	Outcome
Kucukarda et al. [9]	Osteosarcoma	25	Female	Dyspnea and dry cough	Diffuse interstitial	Atezolizumab	24 months	2	Methylprednisolone	Improved
Wu et al. [10]	lung adenocarcinoma	69	Male	intermittent Cough, yellow phlegm and fever	Interstitial changes and GGOs	Sintilimab	6 months	2	Methylprednisolone	Improved
Diamantopoulos et al. [11]	Melanoma	62	Female	Dyspnea and dry cough	Patchy consolidation	Nivolumab	6 months	2	Moxifloxacin and prednisone	Improved
Mandala et al. [12]	Melanoma	64	Female	Short of breath and dyspnea	Diffuse lesions and nodules	Nivolumab	8 months	3	Widespectrum antibiotics and methylprednisolone	Improved
Kimura et al. [13]	Lung adenocarcinoma	62	Male	Dyspnea	GGOs	Nivolumab	7 months	2	Prednisolone	Improved
Kimura et al. [13]	Squamous cell carcinoma	68	Male	/	GGOs	Nivolumab	8 months	1	No treatment	Improved
Nakai et al. [14]	Renal cell carcinoma	50	Male	Intermittently run a fever	GGOs	Nivolumab	142 days	2	Methylprednisolone and mycophenolate mofetil	Improved
Yang et al. [15]	Gastric Cancer	86	Male	Asthma with a low-grade fever	Interstitial pneumonia	Pembrolizumab	2 months	/	Methylprednisolone	Improved
Xie et al. [16]	Large-cell neuroendocrine carcinomas	67	Male	Dyspnea	/	Pembrolizumab	2 weeks	/		Improved
Kimura et al. [13]	Lung adenocarcinoma	69	Male	Respiratory failure	GGOs	Pembrolizumab	4 months	4	Methylprednisolone	Death
This case	Lung adenocarcinoma	77	Female	Fever, fatigue, and dry cough	Multiple patchy high-density areas	Pembrolizumab	2.5 months	3	Methylprednisolone	Improved

CIP: immune checkpoint inhibitor-related pneumonitis; ICIs: immune checkpoint inhibitors; GGOs: ground-glass opacities